India’s pharmaceutical sector is entering a new phase of accelerated growth, with Union Minister Mr. Piyush Goyal inviting global pharmaceutical companies to participate in India’s rapidly expanding healthcare and innovation ecosystem. The announcement was made at the Global Ambassador Meet on the Pharmaceutical Sector, along with the curtain raiser for Global Drug Regulators Conclave (GDRC) 2026 and International Pharma and Healthcare Expo (IPHEX) 2026 in New Delhi.

The statement highlighted that India’s pharmaceutical industry, currently valued at approximately Rs. 5.56 lakh crore (US$ 60 billion), has the potential to double in size over the next five years. This projection reflects India’s growing ambition to evolve from being primarily a global leader in generic medicines to becoming a comprehensive hub for pharmaceutical innovation, advanced drug development, clinical research and high-end manufacturing.

A major focus of the government’s vision is to position India as a trusted and essential part of global healthcare supply chains. With a population of 1.4 billion people, India offers a large domestic market that supports both scale and innovation. At the same time, the country continues to strengthen its export capabilities, making it a key player in global pharmaceutical trade.

The Indian pharmaceutical ecosystem is built on three core pillars as highlighted in the statement: trust, innovation and partnerships. These pillars define India’s strategy to attract global investment and deepen collaboration with international pharmaceutical companies. The government is actively encouraging foreign firms to expand research and manufacturing operations in India, leveraging the country’s cost competitiveness, skilled workforce and strong regulatory framework.

India already holds a dominant position in global healthcare supply chains. The country supplies nearly 65–70% of the World Health Organization’s vaccine requirements, making it one of the largest vaccine producers in the world. This achievement highlights India’s critical role in ensuring global health security, especially during pandemics and public health emergencies.

In addition, India hosts the highest number of US FDA-approved pharmaceutical manufacturing facilities outside the United States, further strengthening its credibility as a high-quality production hub. These facilities adhere to strict global standards, enabling Indian pharmaceutical companies to export medicines to regulated markets across North America, Europe and other regions.

The government also noted a significant rise in patent filings in the pharmaceutical sector, which have nearly doubled in recent years. This indicates a shift in the industry from a focus on generics to a more innovation-driven approach. India is increasingly investing in research and development, biotechnology and advanced drug discovery platforms to strengthen its long-term competitiveness.

To support this transformation, initiatives such as the Biopharma Shakti programme and a Rs. 92,670 crore (US$ 10 billion) innovation support scheme have been introduced. These programmes aim to encourage research-led growth, support startups in biotechnology and strengthen the country’s capabilities in next-generation pharmaceutical development.

The government’s vision is not only focused on industrial growth but also on ensuring equitable healthcare access. During the COVID-19 pandemic, India played a crucial role in supplying affordable medicines and vaccines to more than 100 countries worldwide, reinforcing its position as a responsible global healthcare partner. This contribution has strengthened India’s diplomatic and trade relationships while highlighting its commitment to global health equity.

The Global Drug Regulators Conclave (GDRC) 2026 and IPHEX 2026 events further reflect India’s intention to position itself as a global pharmaceutical and healthcare hub. These platforms provide opportunities for international collaboration, regulatory alignment and business partnerships between Indian and global companies.

A key driver of India’s pharmaceutical growth is its strong manufacturing base, which combines large-scale production capacity with cost efficiency and quality compliance. The industry benefits from integrated supply chains, advanced infrastructure and increasing investment in research parks and biotechnology clusters.

The government’s emphasis on global partnerships is aimed at accelerating innovation and expanding India’s presence in high-value segments such as biologics, biosimilars, specialty drugs and complex generics. These segments are expected to play a major role in the future growth of the global pharmaceutical industry.

Another important factor supporting growth is India’s expanding clinical research ecosystem. With a diverse patient population and improving regulatory frameworks, India is becoming an attractive destination for clinical trials and drug development studies. This enhances the country’s role in the global innovation value chain.

The pharmaceutical sector is also closely linked to India’s broader healthcare reforms, including digital health initiatives, insurance expansion and infrastructure development. Together, these reforms create a strong foundation for sustained industry growth.

In conclusion, India’s pharmaceutical industry is entering a transformative phase driven by innovation, global collaboration and strong policy support. The government’s invitation to international pharmaceutical companies reflects a strategic push to integrate India more deeply into the global healthcare ecosystem.

With strong manufacturing capabilities, rising research activity and expanding global partnerships, India is well-positioned to achieve its goal of becoming a world-leading pharmaceutical innovation hub. As the industry moves toward doubling its value in the next five years, India is set to play an even more influential role in shaping the future of global healthcare and medicine production.